Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYE National Vision	$21.51 +0.7%	$16.01	$9.56 ▼ $21.84	$1.70B	1.24	1.87 million shs	2.64 million shs
GKOS Glaukos	$97.69 +0.1%	$92.45	$77.10 ▼ $163.71	$5.58B	0.8	724,367 shs	797,469 shs
IRTC iRhythm Technologies	$143.85 -1.1%	$125.86	$55.92 ▼ $150.00	$4.59B	1.4	481,585 shs	307,516 shs
TMDX TransMedics Group	$142.88 -0.1%	$107.25	$55.00 ▼ $177.37	$4.83B	2.1	1.36 million shs	454,578 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYE National Vision	-0.51%	+2.44%	+13.31%	+83.43%	+49.55%
GKOS Glaukos	-1.92%	+5.21%	+5.56%	-4.97%	-14.23%
IRTC iRhythm Technologies	-1.29%	+0.17%	+4.08%	+44.51%	+57.28%
TMDX TransMedics Group	+0.11%	+5.49%	+17.14%	+108.73%	+0.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EYE National Vision	3.2971 of 5 stars	2.2	4.0	3.3	3.4	0.8	0.0
GKOS Glaukos	4.4296 of 5 stars	4.4	2.0	4.4	1.6	2.5	0.6
IRTC iRhythm Technologies	1.2985 of 5 stars	2.5	3.0	0.0	2.1	0.0	0.6
TMDX TransMedics Group	1.3413 of 5 stars	1.4	2.0	0.0	1.5	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EYE National Vision	2.44	Hold	$17.75	-17.48% Downside
GKOS Glaukos	2.75	Moderate Buy	$134.67	37.85% Upside
IRTC iRhythm Technologies	2.91	Moderate Buy	$136.45	-5.14% Downside
TMDX TransMedics Group	2.80	Moderate Buy	$125.11	-12.44% Downside

Current Analyst Ratings Breakdown

Latest EYE, GKOS, TMDX, and IRTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	IRTC iRhythm Technologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $160.00
6/4/2025	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$125.00 ➝ $145.00
6/3/2025	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/22/2025	IRTC iRhythm Technologies	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$130.00 ➝ $167.00
5/19/2025	EYE National Vision	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Perform ➝ Market Perform	$13.00 ➝ $19.00
5/12/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$14.00 ➝ $17.00
5/9/2025	EYE National Vision	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$13.00 ➝ $17.00
5/9/2025	EYE National Vision	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$13.00 ➝ $21.00
5/9/2025	TMDX TransMedics Group	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$125.00 ➝ $130.00
5/9/2025	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00 ➝ $125.00
5/8/2025	EYE National Vision	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $20.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EYE National Vision	$1.85B	0.92	$3.06 per share	7.03	$10.60 per share	2.03
GKOS Glaukos	$404.52M	13.80	N/A	N/A	$9.46 per share	10.33
IRTC iRhythm Technologies	$618.59M	7.42	N/A	N/A	$6.85 per share	21.00
TMDX TransMedics Group	$488.23M	9.90	$0.27 per share	530.08	$4.20 per share	34.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EYE National Vision	-$65.90M	-$0.33	N/A	79.67	3.27	-0.81%	3.52%	1.39%	8/6/2025 (Estimated)
GKOS Glaukos	-$134.66M	-$2.37	N/A	N/A	N/A	-39.04%	-16.53%	-10.61%	7/30/2025 (Estimated)
IRTC iRhythm Technologies	-$123.41M	-$3.14	N/A	N/A	N/A	-19.14%	-118.83%	-11.34%	7/30/2025 (Estimated)
TMDX TransMedics Group	-$25.03M	$1.36	152.00	99.92	N/A	8.14%	18.74%	4.39%	7/30/2025 (Estimated)

Latest EYE, GKOS, TMDX, and IRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	TMDX TransMedics Group	$0.29	$0.70	+$0.41	$0.70	$123.39 million	$143.54 million
5/7/2025	Q1 2025	EYE National Vision	$0.32	$0.34	+$0.02	$0.18	$510.30 million	$510.32 million
5/1/2025	Q1 2025	IRTC iRhythm Technologies	-$0.89	-$0.95	-$0.06	-$0.97	$153.39 million	$158.68 million
4/30/2025	Q1 2025	GKOS Glaukos	-$0.33	-$0.22	+$0.11	-$0.32	$102.78 million	$106.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EYE National Vision	N/A	N/A	N/A	N/A	N/A
GKOS Glaukos	N/A	N/A	N/A	N/A	N/A
IRTC iRhythm Technologies	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EYE National Vision	0.30	0.57	0.37
GKOS Glaukos	0.19	5.54	4.71
IRTC iRhythm Technologies	9.00	6.27	6.12
TMDX TransMedics Group	2.42	8.20	7.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EYE National Vision	N/A
GKOS Glaukos	99.04%
IRTC iRhythm Technologies	N/A
TMDX TransMedics Group	99.67%

Insider Ownership

Company	Insider Ownership
EYE National Vision	2.70%
GKOS Glaukos	5.80%
IRTC iRhythm Technologies	1.10%
TMDX TransMedics Group	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EYE National Vision	14,000	79.05 million	76.94 million	Optionable
GKOS Glaukos	780	57.14 million	51.61 million	Optionable
IRTC iRhythm Technologies	1,790	31.93 million	31.09 million	Optionable
TMDX TransMedics Group	210	33.82 million	31.21 million	Optionable

EYE, GKOS, TMDX, and IRTC Headlines

Recent News About These Companies

These 24 Stocks Are Ripe for a Short Squeeze

June 12 at 3:11 PM | schaeffersresearch.com

Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation

June 12 at 10:00 AM | accessnewswire.com

Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May

June 12 at 7:53 AM | marketbeat.com

TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $95,902.80 in Stock

June 11 at 6:51 AM | insidertrades.com

Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 686 Shares of Stock

June 10 at 5:51 PM | marketbeat.com

Kuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law Firm

June 10 at 10:39 AM | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the Investigation

June 10 at 10:00 AM | accessnewswire.com

TransMedics Group, Inc. (TMDX): A Bull Case Theory

June 9, 2025 | insidermonkey.com

TransMedics Group, Inc. (TMDX): A Bull Case Theory

June 9, 2025 | finance.yahoo.com

3 Medical Technology Stocks Outperforming in 2025 (TMDX)

June 9, 2025 | marketbeat.com

TransMedics: Data Points To Strong Second Quarter, But Beware Of The Second Half

June 9, 2025 | seekingalpha.com

GAMMA Investing LLC Boosts Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

June 9, 2025 | marketbeat.com

TransMedics Group, Inc. (TMDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

June 8, 2025 | accessnewswire.com

12,523 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Two Sigma Investments LP

June 8, 2025 | marketbeat.com

Stocks With Rising Composite Ratings: TransMedics Group

June 6, 2025 | msn.com

TransMedics Group (NASDAQ:TMDX) Earns "Overweight" Rating from Piper Sandler

June 6, 2025 | americanbankingnews.com

3 High-Growth Stocks Traders Love and Investors Should Watch (TMDX)

June 5, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect

June 5, 2025 | accessnewswire.com

Sugar Maple Asset Management LLC Makes New $740,000 Investment in TransMedics Group, Inc. (NASDAQ:TMDX)

June 5, 2025 | marketbeat.com

TransMedics Group's (TMDX) Hold Rating Reiterated at Needham & Company LLC

June 5, 2025 | americanbankingnews.com

Piper Sandler Boosts TransMedics (TMDX) PT to $145, Keeps Overweight Rating

June 4, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Buybacks and Big-Time Developments: 3 Stocks Making Huge Moves
By Leo Miller | May 19, 2025
View Buybacks and Big-Time Developments: 3 Stocks Making Huge Moves
Viking Holdings Posts Strong Q1, Eyes Growth Ahead
By Chris Markoch | May 20, 2025
View Viking Holdings Posts Strong Q1, Eyes Growth Ahead
Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades
By Thomas Hughes | May 16, 2025
View Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades
Keep Your EYE on This Stock, It Just Got a Rare Double Upgrade
By Sam Quirke | May 15, 2025
View Keep Your EYE on This Stock, It Just Got a Rare Double Upgrade
3 Small-Cap Stocks With Room to Run Despite Tariff Headwinds
By Chris Markoch | May 16, 2025
View 3 Small-Cap Stocks With Room to Run Despite Tariff Headwinds

EYE, GKOS, TMDX, and IRTC Company Descriptions

National Vision NASDAQ:EYE

$21.51 +0.14 (+0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$21.74 +0.23 (+1.09%)

As of 04:26 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

Glaukos NYSE:GKOS

$97.69 +0.09 (+0.09%)

Closing price 03:59 PM Eastern

Extended Trading

$97.64 -0.05 (-0.06%)

As of 04:04 PM Eastern

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

iRhythm Technologies NASDAQ:IRTC

$143.85 -1.63 (-1.12%)

Closing price 04:00 PM Eastern

Extended Trading

$143.83 -0.02 (-0.01%)

As of 04:20 PM Eastern

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

TransMedics Group NASDAQ:TMDX

$142.88 -0.17 (-0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$142.26 -0.62 (-0.43%)

As of 04:33 PM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time